The goal of this clinical trial is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of Alport syndrome (AS) in a randomized, single-blind, placebo-controlled trial, to provide a clinical basis for the development of stem cell products for the treatment of AS, and to further clarify the therapeutic effect of hUC-MSC in the treatment of AS.
3 years old ≤Age ≤ 12 years old;
Meet the diagnostic criteria of Alport syndrome;
Positive proteinuria or combined hematuria;
Chronic kidney disease (CKD) stage: I-III stage children, that is, glomerular filtration rate greater than 60 ml/min.1.73m2;
Age <3 years or >12 years old;
Alport syndrome patients with only microscopic hematuria and normal glomerular filtration rate;
Patients with significantly reduced renal function, chronic kidney disease stage IV or V, Alport syndrome;
Patients with other renal diseases;